SFSabine Annemijn Fuchs

Sabine Annemijn Fuchs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabine Annemijn Fuchs has a total of 410 co-authors. Here are the top co-authors by number of shared publications:

  • Edward E. S. Nieuwenhuis

    Erasmus MC Rare Disease Center, Department of Pediatrics, Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands

    7 shared publications
  • Imre F. Schene

    Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands

    7 shared publications
  • Peter M. van Hasselt

    Affiliation Department of Metabolic Diseases, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands

    7 shared publications
  • Gautam Kok

    Department of Metabolic Diseases, Wilhelmina Children’s Hospital, Utrecht, The Netherlands

    6 shared publications
  • Ruud Berger

    University Medical Center Utrecht

    6 shared publications
  • Tom J. de Koning

    Department of Pediatrics, Lund University, Lund, Sweden

    6 shared publications

Latest Publications

  • Open Access

    Tailored Amino Acid Treatment for Pediatric Patients With Mitochondrial Aminoacyl‐ tRNA Synthetase Deficiencies

    by I. J. J. Muffels, G. Kok, Z. Tang, L. S. Medeiros, F. O. Poswar, W. P. Vermeij, R. Rodenburg, K. Smit, S. K. Sukumaran, S. B. Wortmann, et al.

    Aminoacyl‐tRNA synthetases (ARSs) facilitate the loading of transfer RNAs with their cognate amino acids in the cytosol (ARS1), mitochondria (ARS2), or both (dual ARS). ARS deficiencies are clinically heterogeneous and can cause severe, occasionally fatal disease. Supplementation with cognate amino acids to prevent local amino acid depletion has shown promise in ARS1 deficiencies, but its potential in ARS2 deficiencies remains largely unexplored. We investigated the effects of cognate amino acid depletion on mitochondrial function in fibroblasts from seven patients with ARS2 deficiencies using Seahorse respirometry and imaging flow cytometry. During amino acid depletion, patient fibroblasts showed decreased mitochondrial membrane potential and reduced basal and maximal respiratory capacity. We additionally evaluated oral cognate amino acid supplementation in nine patients with SARS2, EARS2, LARS2, WARS2, FARS2, or VARS2 deficiencies. Supplementation was well tolerated, with no adverse effects observed. Several patients showed clinical improvements during treatment, including improved development, increased growth, and/or improved cardiac function. In two patients, treatment discontinuation coincided with severe neurological regression. Together, these findings demonstrate that assessing mitochondrial function during cognate amino acid depletion provides a novel functional assay for ARS2 deficiencies that may aid variant interpretation and supports a biological rationale for cognate amino acid supplementation. Clinical supplementation was well tolerated and showed preliminary beneficial effects. These findings support further investigation of cognate amino acid supplementation as a potential supportive treatment strategy for patients with ARS2 deficiencies.

  • Open Access

    Dried Urine Spots for Quantification of C0 (Free) Carnitine Excretion: A Validated Method for Follow-Up and Confirmatory Testing of Primary Carnitine Deficiency

    by Maria van der Ham, Sacha Ferdinandusse, Mirjam Langeveld, Sabine A. Fuchs, Monique G. M. de Sain van der Velden, on behalf of the ODIN Study Group

    Primary carnitine deficiency (PCD), caused by Organic Cation Transporter Novel 2 (OCTN2) deficiency, is detected by newborn screening (NBS) through low blood free carnitine (C0) concentrations. Confirmation of the diagnosis may be supported by demonstrating increased urinary C0 excretion, but urine collection in newborns is technically challenging. We developed and validated a dried urine spot (DUS) method for quantifying urinary C0 excretion as a practical, non-invasive alternative to conventional liquid urine sampling. This approach has the potential to allow parents to obtain urine at home by placing filter paper cards between the baby’s skin and a dry diaper, simplifying sample collection. C0 carnitine and creatinine were quantified in 6 mm DUS punches by flow injection analysis–tandem mass spectrometry (FIA–MS/MS) following butylation. The method was analytically validated for sensitivity, precision, stability, and agreement with liquid urine measurements. The method demonstrated excellent analytical performance, with lower limits of detection (LLOD)/lower limits of quantification (LLOQ) values of 0.02/0.07 µmol/L for C0 and 0.01/0.04 mmol/L for creatinine. Normalization of C0 to creatinine reduced variability related to sampling and punch location. Both analytes remained stable in DUS for at least 10 days at room temperature and after 11 freeze–thaw cycles. C0/creatinine obtained from DUS showed excellent agreement with liquid urine (R2 > 0.9967), although concentrations were consistently lower, requiring a correction factor of 1.27 to estimate concentrations equivalent to liquid urine. DUS provides a reliable and accurate alternative to liquid urine for measuring C0 excretion in newborns. This simple, home-based sampling approach facilitates non-invasive urine collection and has the potential to support follow-up and confirmatory testing of PCD.

  • Open Access

    Aminoacyl‐ tRNA Synthetases: Variant Classification, Functional Assays, and Emerging Therapeutic Strategies

    by M. I. Mendes, D. E. Smith, V. Spek, A. M. Bosch, W. E. Corpeleijn, M. Engelen, S. A. Fuchs, A. Hadchouel, I. U. Heinemann, R. H. Houtkooper, et al.

    Aminoacyl‐tRNA synthetases (aaRS) are essential enzymes that charge tRNAs with their corresponding amino acids, playing a critical role in protein synthesis. All 37 nuclear‐encoded ARS genes, comprising both cytosolic ( ARS1 ) and mitochondrial ( ARS2 ) isoforms, have now been linked to human disease. Pathogenic variants in these genes cause a wide range of phenotypes, from dominant peripheral neuropathies to recessive multisystemic disorders. Despite the high number of ARS variants identified, functional validation remains difficult, with over 80% of missense variants classified as VUS in public databases. Additionally, the role of non‐canonical aaRS functions in disease remains an area requiring further exploration. Our laboratory developed a high‐throughput LC–MS/MS‐based aminoacylation assay to measure aaRS activity in patient‐derived fibroblasts, aiding in variant classification. This functional approach has contributed to the diagnosis of nearly 200 patients and has uncovered complex variant effects, including thermolabile and splicing‐defective forms. Therapeutically, amino acid supplementation and dietary interventions have shown effect in select cases, while gene therapy is being explored for dominant ARS‐related neuropathies. Amenability to targeted interventions further underlines the need for correct interpretation of genetic variants, which are increasingly recognized as genetic testing is progressively used in the diagnostic work‐up and functional assays. Additionally, natural history studies are essential to improve diagnosis, understand disease mechanisms, and guide and evaluate personalized treatment. This review underscores the critical need for integrated genomic and functional approaches to advance variant interpretation and therapeutic development in the era of NGS.


  • Open Access

    Organoids for Metabolic Disease Modeling

    by Arif Ibrahim Ardisasmita, Edward Eelco Salomon Nieuwenhuis, Sabine Annemijn Fuchs

    Inherited metabolic diseases (IMDs) are a diverse group of rare genetic disorders that disrupt metabolic pathways, leading to severe clinical manifestations. Disease models ranging from complex animal models to simple in vitro systems have provided insights into IMDs, but each has limitations. Organoids, three‐dimensional in vitro models, bridge this gap by replicating key metabolic functions that are absent in most simple 2D cell models. While organoids do not fully mimic organ complexity, they effectively model disease‐specific metabolic defects, as seen in methylmalonic acidemia, Wilson's disease, and cystic fibrosis. Recognizing that function is more critical than organ resemblance, we propose focusing on the specific function of interest rather than selecting a model solely based on its derivation from the most affected organ. Focusing on specific biological processes enables precise, disease‐relevant studies that drive novel therapeutic strategies and personalized medicine.

  • Open Access

    Direct Prediction of VLCADD Severity Using Newborn Screening Analyte Data

    by Marit Schwantje, Rose E. Maase, Eugenie Dekkers, Sacha Ferdinandusse, Frédéric M. Vaz, Friederieke Hörster, Ulrike Mütze, Sarah C. Grünert, Gepke Visser, Monique G. M. De Sain‐Van der Velden, et al.

    A critical concern of newborn screening (NBS) for very‐long chain acyl‐CoA dehydrogenase deficiency (VLCADD) is the difficulty of predicting clinical outcomes. To address this, we investigated neonatal C18:2‐carnitine concentrations as a possible predictor of VLCADD phenotype. To investigate the impact of sex, gestational age (GA) at birth, sampling day and birth weight on C18:2‐carnitine, we analyzed NBS‐dried blood spots (DBS) from Dutch newborns born between 2018 and 2020 ( n = 209.785). After normalization for resulting confounders, C18:2‐carnitine concentrations were investigated in NBS‐DBS ( n = 15) and neonatal plasma ( n = 35) of Dutch VLCADD‐patients, and in German NBS‐DBS ( n = 6) and correlated with clinical severity and diagnostic assays. Results showed that C18:2‐carnitine concentrations were affected by GA, sampling day, birth weight and, to a lesser extent, by sex. High C18:2‐carnitine, normalized for GA, sampling day and birth weight, reliably identified all VLCADD‐patients with (expected) severe phenotypes. The differentiating C18:2‐carnitine was identified as linoleylcarnitine. In conclusion, this study shows that neonatal C18:2‐carnitine concentrations can serve to predict disease severity directly after positive NBS for VLCADD. Patients with high C18:2‐carnitine concentrations can be considered “severe” and require strict dietary treatment and close monitoring. Patients with low C18:2‐carnitine concentrations can be identified as “mild” and only need preventive dietary measures.


  • Open Access

    Too Early to Tell? Balancing Diagnostic Accuracy of Newborn Screening for Propionic Acidemia Versus a Timely Referral

    by Nils W. F. Meijer, Hidde H. Huidekoper, Klaas Koop, Sabine A. Fuchs, M. Rebecca Heiner Fokkema, Charlotte M. A. Lubout, Andrea B. Haijer-Schreuder, Wouter F. Visser, Rendelien K. Verschoof-Puite, Eugènie Dekkers, et al.

    In the Netherlands, the newborn screening (NBS) program includes screening for propionic aciduria (PA) and methylmalonic aciduria (MMA). When initial screening reveals elevated C3 concentrations or abnormal ratios (C3/C2, C3/C16), a second-tier test measuring methylcitric acid (MCA) for PA and methylmalonic acid (MMAmb) for MMA is performed. While this two-tier approach reduces false positives effectively, it can delay referral from the NBS program and diagnosis of propionic aciduria. We describe four early-onset PA cases in which the current Dutch screening algorithm negatively impacted clinical outcomes, highlighting the need for expedited referral. We investigated different alternative screening strategies to identify the most effective approach for improving timeliness, while maintaining the high specificity of Dutch PA NBS. This revised approach prioritizes the evaluation of the C3/C2 ratio in first-tier screening. Specifically, samples with a C3/C2 ratio ≥ 0.75 should be referred directly for medical consultation and confirmatory testing. For all other samples with less pronounced biochemical abnormalities, the existing two-tier screening algorithm remains an appropriate NBS protocol. To position our approach internationally, a survey of European NBS programs was conducted to compare screening and referral protocols for PA across the region.


  • Open Access

    Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases

    by J.A. Castro-Alpízar, M.J. Lenderink, E.E.S. Nieuwenhuis, S.A.A. Kooijmans, S.A. Fuchs


  • Open Access

    The Genotypic and Phenotypic Spectrum of GOSR2 Mutations: Clinical and Pathophysiological Insights

    by Sjoukje S. Polet, Elisabeth Z. Siegal, Sabine A. Fuchs, Marina A. J. Tijssen, Tom J. de Koning

    North Sea‐Progressive Myoclonus Epilepsy (NS‐PME) is a progressive neurological disorder, initially only associated with the homozygous GOSR2 founder mutation (c.430G>T; p.Gly144Trp). Clinical symptoms include untreatable early‐onset ataxia, cortical myoclonus and epilepsy. Recently, the spectrum of GOSR2 mutations and associated phenotypic variability has expanded. To improve care and to facilitate genotype–phenotype predictions for NS‐PME patients, we systematically reviewed all reported GOSR2 mutations, clinical phenotypes, and pathophysiological findings. A narrative review literature search was conducted in PubMed, EMBASE, and Web of Science (1985—August 2024) using the keywords “GOSR2”, “GS27 protein”, “Bos1”, and “Membrin”. Only studies in English and specifically studies on GOSR2 function, pathogenic variants, clinical manifestations, and potential therapies were included. A total of 42 patients with 11 different GOSR2 mutations were identified. Three main phenotypes were observed: progressive myoclonus ataxia/epilepsy (PMA/PME), congenital muscular dystrophy, and hearing loss. Orthopedic abnormalities were frequently reported. Intercurrent infections or fever often led to a worsening of symptoms. Glycosylation defects were reported in several compound heterozygous GOSR2 variants. Molecularly, GOSR2 mutations result in (partial) loss of function of the GOSR2/SNARE complex, with mutation severity and the involvement of specific isoforms contributing to phenotypic variability. GOSR2 mutations lead to progressive neurological disorders, primarily characterized by myoclonus ataxia/epilepsy, muscular dystrophy, and hearing loss. The genotypic background of NS‐PME has expanded with pathogenic biallelic GOSR2 variants beyond the original homozygous founder mutation. Understanding the clinical spectrum and molecular mechanisms of GOSR2‐related diseases may facilitate more targeted treatment strategies as well as better‐informed phenotype predictions.


  • Open Access

    Myopathic Symptoms and Exercise Tolerance in Adolescent Patients With Long‐Chain Fatty Acid Oxidation Disorders

    by Marit Schwantje, Marco van Brussel, Tim Takken, Monique G. M. de Sain‐Van der Velden, Mirjam Langeveld, Gepke Visser, Sabine A. Fuchs

    Long‐chain fatty acid oxidation disorders are characterized by rhabdomyolysis, often provoked by physical exercise. For the newborn screening (NBS) cohort, it remains uncertain to what extent they will develop the myopathic phenotype. This study assesses physiological responses to exercise, muscle symptoms, and activity levels in 14 adolescent lcFAOD patients (VLCADD ( n = 8), LCHADD ( n = 4), CPT2D ( n = 1) and LCKATD ( n = 1); ages 9.9–17.8 years). Analyses of incremental and prolonged cardiopulmonary exercise tests, a symptom‐based questionnaire, and the Short Questionnaire to Assess Health‐enhancing physical activity were performed. The results revealed a decreased ventilatory anaerobic threshold compared to control data (z‐score − 0.5 (0.8) [median (interquartile range (IQR))], p = 0.001) and, on average, a decreased relative peak oxygen uptake (z‐score − 1.3 (2.8), p = 0.005) and relative peak work rate (z‐score − 0.7 (1.3), p = 0.03). There were no adverse events during and following prolonged exercise under well‐fed circumstances (based on symptoms and post‐exercise creatine kinase). The symptom‐based questionnaire revealed that the presence of provoking factors (e.g., infection, inadequate intake) increased the risk of rhabdomyolysis during/after exercise. Screening ( n = 11) and symptomatically ( n = 3) diagnosed patients showed normal levels of physical activity (medians: 3.5 h per week) compared to their healthy peers (3.2 h), despite debilitating muscle pain in 46% of the by screening and all of the symptomatically diagnosed patients. In conclusion, patients with seemingly normal exercise patterns reported debilitating muscle symptoms and rhabdomyolysis, especially when additional provoking factors were present. Exercise tests may provide a valuable tool to monitor and guide exercise potential in these new NBS cohorts.


  • Open Access

    Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors

    by Indi P. Joore, Sawsan Shehata, Irena Muffels, Jose Castro-Alpízar, Elena Jiménez-Curiel, Emilia Nagyova, Natacha Levy, Ziqin Tang, Kimberly Smit, Wilbert P. Vermeij, et al.

    Mutations in the mitochondrial genome can cause maternally inherited diseases, cancer, and aging-related conditions. Recent technological progress now enables the creation and correction of mutations in the mitochondrial genome, but it remains relatively unknown how patients with primary mitochondrial disease can benefit from this technology. Here, we demonstrate the potential of the double-stranded DNA deaminase toxin A-derived cytosine base editor (DdCBE) to develop disease models and therapeutic strategies for mitochondrial disease in primary human cells. Introduction of the m.15150G > A mutation in liver organoids resulted in organoid lines with varying degrees of heteroplasmy and correspondingly reduced ATP production, providing a unique model to study functional consequences of different levels of heteroplasmy of this mutation. Correction of the m.4291T > C mutation in patient-derived fibroblasts restored mitochondrial membrane potential. DdCBE generated sustainable edits with high specificity and product purity. To prepare for clinical application, we found that mRNA-mediated mitochondrial base editing resulted in increased efficiency and cellular viability compared to DNA-mediated editing. Moreover, we showed efficient delivery of the mRNA mitochondrial base editors using lipid nanoparticles, which is currently the most advanced non-viral in vivo delivery system for gene products. Our study thus demonstrates the potential of mitochondrial base editing to not only generate unique in vitro models to study these diseases, but also to functionally correct mitochondrial mutations in patient-derived cells for future therapeutic purposes.